Are you looking for influenza vaccine market data - answers to benefit your work? Our new report shows you revenue prospects for the manufacture and sale of influenza vaccines from 2009 to 2021.
There, you will see commercial opportunities for influenza vaccines - original research, data and opinions. By ordering now, you can stay ahead. We aim to save you time and aid your decisions.
Our report shows revenue opportunities at world, company, product and national levels. You can assess the high growth potential of the influenza vaccine industry and market now.
Which influenza market areas will grow fastest this decade? What are the technological and commercial trends to watch? How will national and world markets for influenza vaccines perform from 2011 to 2021?
Our study answers those questions and others for the influenza vaccines market. We show you where the industry is heading from 2011 - events, technologies and revenues.
What are leading companies doing, and how is competition shaping up? You will see trends in influenza vaccine research and development.
Our new report shows you developments to watch, including multivalent vaccines, faster, more flexible manufacturing, emerging markets and pediatric vaccines.
You can assess the influenza industry's strengths, weaknesses, trends and revenue prospects from 2011. You will see opportunities for influenza vaccine products.
Here, you can find data, analyses and opinion to benefit your research, calculations, meetings and presentations. Respond now to get that information.
Analysis and expert opinion to help your work - so you won't be left behind
Our new report gives you revenue forecasts, growth rates, market share analysis, SWOT analysis, an R&D review and expert opinion. We include 132 tables and charts and four interviews (shown in the accompanying lists).
World Influenza Vaccines Market 2011-2021 shows you revenue trends, opportunities and challenges
Our report gives you the following advantages:
• You will receive hard data for the influenza vaccine industry - especially our revenue forecasts to 2021
• You will discover sales trends for the overall market and its main components from 2009 to 2021 - seeing where commercial growth will occur
• You will find revenue forecasts for leading products and companies from 2011 to 2021, with discussions of market potential and competition
• You will find revenue forecasts for leading national markets from 2011 to 2021 (US, Japan, UK, Germany, France, Spain, Italy, China and India)
• You will receive influenza vaccine production, distribution, pricing and coverage data
• You will learn how the influenza vaccines industry can change from 2011 to 2021
• You will assess leading companies in influenza vaccines, discovering their activities, outlook and revenue prospects
• You will investigate competition and opportunities influencing the influenza vaccine industry from 2011 onwards
• You will see what stimulates and restrains the industry and market - from the present onwards - including national and international policy
• You will review influenza vaccine technologies, assessing R&D potential
• You will investigate commercial requirements - with therapeutic needs and commercial opportunities discussed
• You will analyse opportunities for established companies and those seeking to enter the market
• You will view expert opinion from our survey, including full interview transcripts.
That combination of quantitative and qualitative market analysis sets our report apart. We give you original market predictions, found only in our work.
You can order our new report, receiving the market information you need
Our report can benefit everybody interested in the manufacture, sale and distribution of influenza vaccines. You will see where the industry is heading, assessing the opportunities, needs and challenges.
Order our report now, making sure you don't miss out. Please let us help in your work.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
NB: All visiongain reports are password locked so please let us know what licence is most suitable for your business needs
Global Drug And Medication Industry
Table of Contents
1. Executive Summary
1.1 Influenza Vaccines Market Review
1.2 Aims, Scope and Format of the Report
1.3 Research & Analysis Methods
2. Introduction to Influenza and its Treatment
2.1 What is Influenza?
2.2 What is the Social and Economic Burden?
2.3 Who are at Risk?
2.4 How does Influenza Spread?
2.5 Symptoms of Influenza
2.6 About the Influenza Virus
2.6.1 Antigenic Drift
2.6.2 Antigenic Shift
2.7 Seasonal Influenza Epidemic
2.8 How is Influenza Diagnosed?
2.9 Treatment of Influenza
2.9.1 Use of Antiviral Agents
2.9.2 Vaccination
2.9.2.1 Seasonal Influenza Vaccines
2.9.2.2 Pandemic Influenza Vaccines
2.9.2.3 'Pre-Pandemic' Influenza Vaccines
2.10 Types of Influenza Vaccine
2.10.1 Trivalent Inactivated Vaccines (TIV)
2.10.2 Trivalent Live Attenuated Influenza Vaccine (LAIV)
2.11 Methods of Vaccine Production
2.11.1 Egg-Based Manufacturing Technology
2.11.2 Cell-Based Manufacturing Technology
2.11.2.1 MCDK (Madin Darby Canine Kidney Cells)
2.11.2.2 Vero Cells
2.11.2.3 Per C6 Cells
2.11.3 Cell-Based Technique has an Edge over Egg-Based Vaccine Production
2.11.4 Steps Involved in Vaccine Production
2.11.5 Distribution of Vaccine
2.12 Influenza Pandemics - The New Threat
2.12.1 Increasing Global Vaccine Access to Combat Pandemic Influenza
2.12.2 Government Policy Regarding Pandemic Influenza Vaccines in the Mature Markets
3. The Influenza Vaccine Market - Global, Mature and Emerging
3.1 Challenges of the Global Influenza Vaccine Market
3.2 The Global Influenza Market Worth $4.3bn in 2009
3.3 The Global Market Projected to Grow to 2021
3.4 The Mature Market Projected to Maintain Steady Growth
3.5 The Emerging & Other Markets Projected to Expand Rapidly
3.6 The Growth Rate of the Emerging & Other Market Category Projected to be the Highest
4. Analysis of the Leading Players in the Influenza Vaccines Market
4.1 Influenza Vaccine Sales Estimate for Sanofi Pasteur
4.1.1 Fluzone/Vaxigrip
4.1.2 Investing in Building Capacity
4.2 Novartis Influenza Vaccines Sales to 2021
4.2.1 Fluvirin
4.3 GlaxoSmithKline PLC
4.3.1 GSK's Acquisition of ID Biomedical
4.3.2 Fluviral/FluLaval
4.3.3 Fluarix
4.3.4 Key Contracts Announced by GSK to Date
4.4 Other Manufacturers in the Mature Markets
4.4.1 Sales Forecasts for Influvac, Flumist and Inflexal
4.5 The Top Players are Building Global Manufacturing Capacities
4.6 The Key Players are Increasing Manufacturing Capacity in the Emerging Markets
5. Analysis of Mature Markets - the US, Japan, Germany, France, Italy, Spain and the UK
5.1 The Mature Market Predicted to Grow Steadily to 2021
5.1.1 Most of the Global Manufacturing Capacity is in the Developed Countries
5.2 EU5 - UK, Germany, France, Spain and Italy
5.2.1 Growth Rates of UK, Germany, France, Spain and Italy Predicted to Remain Steady
5.2.2 Vaccine Coverage Rates Differ Widely Across Target Groups and Countries in the EU
5.2.2.1 Strong Governmental Policies would Help to Achieve the WHO Objectives
5.2.2.2 The GP is at the Centre of the System in France
5.2.2.3 Increasing Influenza Vaccine Coverage: Funding for Regional Authorities in Italy
5.2.2.4 Enhancing Awareness in Germany
5.3 The United States
5.3.1 The Influenza Vaccines Market in the US is Expected to Grow to 2021
5.3.2 Sanofi Pasteur is the Market Leader in the US
5.3.3 Seasonal Influenza Vaccine Supply in US
5.3.4 Vaccine Coverage Rate in the US
5.3.4.1 Vaccine Coverage among Adults in the US
5.3.4.2 Favourable Reimbursement Schemes have Helped Increase Vaccination Rates
5.3.4.3 US Influenza Vaccine Prices Start to Drop
5.4 Japan
5.4.1 The Influenza Vaccine Market Expected to Grow in Japan
5.4.2 Low Vaccine Coverage Rates in Japan
5.4.3 Influenza Vaccine Prices in Japan
5.4.4 Regional Manufacturers Lead the Influenza Vaccine Market in Japan
6. Analysis of the Emerging Markets with Focus on China and India
6.1 An Overview
6.2 The Emerging Market Expected to Grow Significantly to 2021
6.3 China
6.3.1 Demographic Trends - Demand for Influenza Vaccines to Show Strong Growth
6.3.2 The Regulatory Environment in China is Complex
6.3.3 Vaccine Coverage Rates in China are Low
6.3.4 Key Players in the Chinese Market
6.3.5 Influenza Vaccine Sales Will Grow by 20% in China
6.4 India
6.4.1 Demographic Trends - Ageing Population in India to Grow by 15%
6.4.2 Merely 5% of GDP Spent on Healthcare System in India
6.4.3 High Incidence of Influenza among Children
6.4.4 Only a Small Amount of Drugs are Reimbursed in India
6.4.5 The Influenza Vaccine Market in India has Growth Potential
6.4.6 Key Constraints in the Influenza Vaccines Market in India
6.4.7 Influenza Vaccine Sales will Grow Significantly in India
6.4.8 Summary of Influenza Vaccine Sales in the Emerging Markets
7. Forces Affecting the Global Influenza Vaccines Market
7.1 SWOT Analysis of the Influenza Vaccines Market, 2010-2020
7.2 Influenza Vaccines: Manufacturers, International Health Agencies and Governments Show Commitment
7.3 Pandemic Preparedness
7.4 The Market has Weaknesses and Threats
7.5 Manufacturers Anxious about Strict and Lengthy Regulatory Procedures
7.6 The Anti-Vaccine Movement
7.6.1 Campaigns about Side-Effects of Vaccines
7.6.2 Controversy Surrounding Mercury-Containing Vaccines
7.6.3 Consequences of Anti-Vaccine Campaigns
7.7 Vaccines in the Developing World
7.7.1 Vaccine Distribution Networks and the Cold Chain
7.7.2 Vaccine Costs in Developing Countries
7.8 Pandemic Threats Create Demand for Vaccines
7.9 Towards a Universal Influenza Vaccine
7.10 Other Factors Influencing Growth in Influenza Market
7.10.1 Changing World Demographics
7.10.2 Population Increase
7.10.3 Emerging-Market Economies
8. R&D Pipeline Developments in the Influenza Vaccines Industry
8.1 Sanofi Pasteur
8.1.1 Increased Production Capacity of Fluzone
8.1.2 Influenza Vaccine Using PER.C6 Technology - Flucell
8.1.3 Novel Intradermal Delivery System - Flumicro
8.1.4 Universal Influenza A Recombinant Vaccine - ACAM Flu A
8.1.5 Pandemic Preparedness: Vaccine against H5N1 Virus (Avian Flu)
8.1.6 Pandemic Preparedness: Vaccine against H1N1 Virus (Swine Flu)
8.2 Novartis
8.2.1 Acquisition of Chiron - Optaflu Cell-Based Vaccine
8.2.2 Investigational Pre-Pandemic Vaccine AFLUNOV
8.2.3 Alliance with Intercell AG - Use of Next-Generation IC31 Adjuvant
8.2.4 Fluad MF59 Adjuvanted Influenza Vaccine More Efficacious than Non-Adjuvanted Influenza Vaccines in Children
8.2.5 Commitment to Pandemic Preparedness
8.2.6 FDA Approves Agriflu
8.3 GlaxoSmithKline PLC
8.3.1 Stockpile Initiative
8.3.2 Prepandrix - The H5N1 Prepandemic Vaccine
8.3.3 Late Phase Studies on New Generation Seasonal Influenza Vaccine
8.4 Other Vaccines in the Pipeline
8.5 Ongoing Studies on Vaccine Development
8.5.1 Universal Influenza Vaccine
8.5.2 Development of Novel Vaccine Delivery Systems
8.5.3 Pandemic Vaccine
8.5.4 Global Pandemic Influenza Action Plan (GAP) by the WHO
8.5.4.1 New Production Facilities
8.5.4.2 GAP Initiatives to Fund Influenza R&D
8.5.4.3 Constraints Faced by Research and Development
8.5.4.4 Steps Taken to Overcome Constraints
8.5.4.5 An Example of Technology Transfer in India
9. Experts' Views on Influenza Vaccines
9.1 Interview with Richard de Souza, CEO, Archimedes Pharma, and Dr Alan Smith, VP, R&D, Archimedes Development Limited
9.1.1 On the Constraints of Developing a Seasonal Influenza Vaccine
9.1.2 On the Principal Drivers and Restraints in the Influenza Vaccine Market
9.1.3 On Vaccination Coverage Rates in the Mature and Emerging Markets
9.1.4 On Important Pipeline Developments
9.1.5 On Vaccine Development in the Emerging Markets
9.1.6 On the Future of Influenza Vaccines
9.2 Interview with Catherine Ammon, World Heath Organization, Switzerland
9.2.1 On the Preparedness of Countries to Tackle a Pandemic
9.2.2 On the Current and Future Vaccination Rates
9.2.3 On the Most Important Unmet Need for Influenza Management
9.2.4 On the Principal Drivers and Restraints in the Vaccine Market
9.2.5 On the Common Seasonal Influenza Vaccines Used in Switzerland
9.2.6 On the Pipeline Vaccines with Most Promise
9.2.7 Other Comments on Influenza Vaccines and their Future
9.3 Interview with Professor David Bishai, MD, PhD, MPH, Department of Population, Family and Reproductive Health and International Health, Johns Hopkins University, USA
9.3.1 On Strategies for Presenting Vaccination to General Public
9.3.2 On Advantages and Disadvantages of MDVs and PFSs
9.3.3 On Pandemics Preparedness and Intervention
9.4 Interview with Wayne Rudolph, VP, Corporate Development. BiondVax Pharmaceuticals Ltd.
9.4.1 On Unmet Needs in Influenza Management
9.4.2 On the Principal Drivers and Restraints in the Influenza Market
9.4.3 On the Burden of Influenza Epidemics to the Economy
9.4.4 On Current Market for Influenza Vaccines
9.4.5 On Vaccination Rates in Mature and Emerging Markets
9.4.6 On Vaccine Development Capacity in US, EU and Emerging Markets
9.4.7 On BiondVax and Challenges of Developing a Universal Flu Vaccine
9.4.8 On BiondVax Technology for Vaccine Manufacture
9.4.9 On Progress of BiondVax' Universal Flu Vaccine
9.4.10 On R&D in Influenza Vaccines
9.4.11 Pipeline Products from BiondVax
9.4.12 Pipeline Products from Other Manufacturers
9.4.13 On Pandemic Preparedness
10. Conclusions
10.1 Influenza - More Dangerous than Generally Believed Previously
10.2 Vaccines - The Only Way to Contain the Spread
10.3 Influenza Vaccines - Demand vs. Supply
10.4 The Influenza Vaccine Market is Worth Over $4bn Worldwide
10.5 Sanofi Pasteur, GlaxoSmithKline and Novartis - the Top Three Companies in 2010
10.6 The Top Three Companies - Future Sales Growth Possible?
10.7 Future Outlook and Concluding Remarks
List of Tables
Table 2.1 Comparison between TIV and LAIV Technologies
Table 3.1 Global Distribution of Influenza Vaccine Sales ($bn & %), 2009 & 2021
Table 3.2 Projected Market Size ($bn) and Growth Rates (%) of the Global Influenza Vaccine Market, 2009-2015
Table 3.3 Projected Market Size ($bn) and Growth Rates (%) of the Global Influenza Vaccine Market, 2016-2021
Table 3.4 Influenza Vaccine Sales Revenues ($bn) and Growth Rates (%) for Mature Markets (US, Japan and EU5), 2009-2021
Table 3.5 Influenza Vaccine Sales Revenues ($bn) and Growth Rates (%) for Emerging & Other Markets, 2009-2021
Table 4.1 Global Influenza Sales ($bn) and Market Shares (%) for Key Players, 2009, 2010, 2015 and 2021
Table 4.2 Key Mergers and Acquisitions in the Influenza Vaccines Market, 2005-2009
Table 4.3 Global Sales ($m) for Key Influenza Vaccine Producers, 2004, 2008 and 2009
Table 4.4 Global Sales ($m) for Leading Influenza Vaccine Products, 2009, 2010, 2015 and 2021
Table 4.5 Global Influenza Vaccine Sales Revenues ($bn) and Growth Rates (%) for Sanofi Pasteur, 2009-2015
Table 4.6 Global Influenza Vaccine Sales Revenues ($bn) and Growth Rates (%) for Sanofi Pasteur, 2016-2021
Table 4.7 Fluzone/Vaxigrip: Drivers and Restraints, 2009-2021
Table 4.8 Global Sales Forecast ($bn) and Growth Rates (%) for Fluzone/Vaxigrip, 2009-2015
Table 4.9 Global Sales Forecast ($m) and Growth Rates (%) for Fluzone/Vaxigrip, 2016-2021
Table 4.10 Global Influenza Vaccine Sales Revenues ($bn) and Growth Rates (%) for Novartis, 2009-2015
Table 4.11 Global Influenza Vaccine Sales Revenues ($bn) and Growth Rates (%) for Novartis, 2016-2021
Table 4.12 Fluvirin: Drivers and Restraints, 2010-2021
Table 4.13 Global Sales Revenues ($bn) and Growth Rates (%) for Fluvirin, 2009-2015
Table 4.14 Global Sales Revenues ($bn) and Growth Rates (%) for Fluvirin, 2016-2021
Table 4.15 Global Influenza Vaccine Sales Revenues ($bn) and Growth Rates (%) for GlaxoSmithKline, 2009-2015
Table 4.16 Global Influenza Vaccine Sales Revenues ($bn) and Growth Rates (%) for GlaxoSmithKline, 2016-2021
Table 4.17 Fluviral/FluLaval: Drivers and Restraints, 2010-2021
Table 4.18 Global Sales Revenues ($bn) and Growth Rates (%) for FluLaval/Fluviral, 2009-2015
Table 4.19 Global Sales Revenues ($bn) and Growth Rates (%) for FluLaval/Fluviral, 2016-2021
Table 4.20 Fluarix: Drivers and Restraints, 2010-2021
Table 4.21 Global Sales Revenues ($bn) and Growth Rates (%) for Fluarix, 2010-2015
Table 4.22 Global Sales Revenues ($bn) and Growth Rates (%) for Fluarix, 2016-2021
Table 4.23 Potential Worldwide Influenza Vaccine Manufacturers, 2010
Table 4.24 Other Key Influenza Vaccine Manufacturers in Mature Markets, 2010
Table 4.25 Global Influenza Vaccine Sales Revenues ($bn) and Growth Rates (%) for Other Manufacturers, 2009-2015
Table 4.26 Global Influenza Vaccine Sales Revenues ($bn) and Growth Rates (%) for Other Manufacturers, 2016-2021
Table 4.27 Global Sales Revenues ($bn) and Growth Rates (%) for Influvac, Flumist and Inflexal, 2009-2015
Table 4.28 Global Sales Revenues ($bn) and Growth Rates (%) for Influvac, Flumist and Inflexal, 2016-2021
Table 4.29 Projected Global Manufacturing Capacities (Doses) for Key Players, 2012
Table 5.1 Influenza Vaccine Sales Revenues ($bn) and Growth Rates (%) for Mature Markets, 2009-2015
Table 5.2 Influenza Vaccine Sales Revenues ($bn) and Growth Rates (%) for Mature Markets, 2016-2021
Table 5.3 Influenza Vaccine Sales Revenues ($m) and Growth Rates (%) for EU5 Countries, 2009-2015
Table 5.4 Influenza Vaccine Sales Revenues ($m) and Growth Rates (%) for EU5 Countries, 2016-2021
Table 5.5 Influenza Vaccine Sales Revenues ($m) and Growth Rates (%) for EU5 Countries, 2009-2015
Table 5.6 Influenza Vaccine Sales Revenues ($m) and Growth Rates (%) for EU5 Countries, 2016-2021
Table 5.7 Vaccine Coverage Rates (%) in UK, Germany, France, Spain and Italy, 2008-2009
Table 5.8 Influenza Vaccine Sales Revenues ($m) and Growth Rates (%) in the US, 2009-2015
Table 5.9 Influenza Vaccine Sales Revenues ($m) and Growth Rates (%) in the US, 2016-2021
Table 5.10 Top Flu Vaccine Suppliers in the US for the 2008-2009 Season
Table 5.11 Influenza Vaccine Coverage among Adults in the US, 2004-2005
Table 5.12 Influenza Vaccine Coverage among Children in the US, 2004-2005
Table 5.13 Paediatric Influenza Vaccine Price ($) List (May 1, 2009)
Table 5.14 Adult Influenza Vaccines Price ($) List (May 1, 2009)
Table 5.15 Influenza Vaccine Sales Revenues ($bn) and Growth Rates (%) in Japan, 2009-2015
Table 5.16 Influenza Vaccine Sales Revenues ($bn) and Growth Rates (%) in Japan, 2016-2021
Table 5.17 Influenza Vaccine Price ($) per Unit in Japan, 2009-2021
Table 6.1 Influenza Vaccine Sales Revenues ($bn) and Growth Rates (%) for Emerging & Other Markets, 2009-2015
Table 6.2 Influenza Vaccine Sales Revenues ($bn) and Growth Rates (%) for Emerging & Other Markets, 2016-2021
Table 6.3 Leading Influenza Vaccine Manufacturers in Emerging & Other Markets, 2010
Table 6.4 Demographic Statistics for China, 2010
Table 6.5 Estimated Number of Vaccinated People in China, 2009, 2012, 2016 and 2021
Table 6.6 Influenza Vaccine Sales Revenues ($bn) and Growth Rates (%) in China, 2009-2015
Table 6.7 Influenza Vaccine Sales Revenues ($bn) and Growth Rates (%) in China, 2016-2021
Table 6.8 Demographic Statistics for India, 2009
Table 6.9 Estimated Number of Vaccinated People in India, 2010-2021
Table 6.10 Influenza Vaccine Sales Revenues ($bn) and Growth Rates (%) in India, 2009-2015
Table 6.11 Influenza Vaccine Sales Revenues ($bn) and Growth Rates (%) in India, 2016-2021
Table 6.12 Summary of Influenza Vaccine Sales Revenues ($bn) and Growth Rate (%) in Emerging & Other Markets, 2009-2021
Table 7.1 SWOT Analysis: Strengths and Weaknesses of the Global Influenza Vaccines Market, 2011-2021
Table 7.2 SWOT Analysis: Opportunities and Threats in the Global Influenza Vaccines Market, 2011-2021
Table 7.3 Influenza Vaccines Deals and Alliances: Some Recent Examples between Major Pharmaceutical Producers and Companies in Emerging & Other Markets, 2010
Table 8.1 Key Cell-Culture Influenza Vaccines, 2010
Table 8.2 Influenza Vaccine Pipeline for Sanofi Pasteur, 2010
Table 8.3 Influenza Vaccine Pipeline for Novartis, 2010
Table 8.4 Paediatric Influenza Vaccine Pipeline for GlaxoSmithKline, 2010
Table 8.5 Other Influenza Vaccines: Pipeline for GlaxoSmithKline, 2010
Table 8.6 Late-Stage (Registered) Influenza Vaccine Pipeline, 2010
Table 8.7 Mid-Stage (Phase II & III) Influenza Vaccine Pipeline, 2010
Table 8.8 Early-Stage (Phase I) Influenza Vaccine Pipeline, 2010
Table 8.9 Discovery-Stage Influenza Vaccine Pipeline, 2010
Table 8.10 Preclinical-Stage Influenza Vaccine Pipeline, 2010
List of Figures
Figure 2.1 Socio-Economic Burden of Influenza
Figure 2.2 Types of Influenza A Virus
Figure 2.3 Steps Involved in Vaccine Production
Figure 3.1 Global Distribution of Influenza Vaccine Sales (%), 2009
Figure 3.2 Distribution of Influenza Vaccine Sales (%) in Top Five EU Markets, 2009
Figure 3.3 Global Distribution of Influenza Vaccine Sales (%), 2021
Figure 3.4 Distribution of Influenza Vaccine Sales (%) in Top Five EU Markets, 2021
Figure 3.5 Influenza Vaccine Sales Revenues ($bn) for the Global Market, 2009-2021
Figure 3.6 Influenza Vaccine Sales Revenues ($bn) for Mature Markets (US, Japan and EU5), 2009-2021
Figure 3.7 Influenza Vaccine Sales Revenues ($bn) for Global, Mature and Emerging & Other Markets, 2009-2021
Figure 4.1 Global Influenza Vaccine Market Shares (%) for Key Players, 2009
Figure 4.2 Global Influenza Vaccine Market Shares (%) for Key Players, 2010
Figure 4.3 Global Influenza Vaccine Market Shares (%) for Key Players, 2015
Figure 4.4 Global Influenza Vaccine Market Shares (%) for Key Players, 2021
Figure 4.5 Global Sales ($m) for Leading Influenza Vaccine Producers, 2004, 2008 and 2009
Figure 4.6 Global Market Shares (%) for Leading Influenza Vaccine Products, 2009
Figure 4.7 Global Market Shares (%) for Leading Influenza Vaccine Products, 2010
Figure 4.8 Global Market Shares (%) for Leading Influenza Vaccine Products, 2015
Figure 4.9 Global Market Shares (%) for Leading Influenza Vaccine Products, 2021
Figure 4.10 Global Influenza Vaccine Sales Revenues ($bn) and Market Shares (%) for Sanofi Pasteur, 2010-2015
Figure 4.11 Global Influenza Vaccine Sales Revenues ($bn) and Market Shares (%) for Sanofi Pasteur, 2016-2021
Figure 4.12 Global Sales Revenues ($bn) for Fluzone/Vaxigrip, 2009-2015
Figure 4.13 Global Sales Revenues ($bn) for Fluzone/Vaxigrip, 2016-2021
Figure 4.14 Global Influenza Vaccine Sales Revenues ($bn) and Market Shares (%) for Novartis, 2009-2015
Figure 4.15 Global Influenza Vaccine Sales Revenues ($bn) and Market Shares (%) for Novartis, 2016-2021
Figure 4.16 Global Sales Revenues ($bn) and Market Shares (%) for Fluvirin, 2009-2015
Figure 4.17 Global Sales Revenues ($bn) and Market Shares (%) for Fluvirin, 2016-2021
Figure 4.18 Global Sales Revenues ($bn) and Market Shares (%) for GlaxoSmithKline, 2009-2015
Figure 4.19 Global Sales Revenues ($bn) and Market Shares (%) for GlaxoSmithKline, 2016-2021
Figure 4.20 Global Sales Revenues ($bn) and Market Shares (%) for FluLaval/Fluviral, 2009-2015
Figure 4.21 Global Sales Revenues ($bn) and Market Shares (%) for FluLaval/Fluviral, 2016-2021
Figure 4.22 Global Sales Revenues ($bn) and Market Shares (%) for Fluarix, 2009-2015
Figure 4.23 Global Sales Revenues ($bn) and Market Shares (%) for Fluarix, 2016-2021
Figure 4.24 Global Sales Revenues ($bn) and Market Shares (%) for Other Manufacturers, 2009-2015
Figure 4.25 Global Sales Revenues ($bn) and Market Shares (%) for Other Manufacturers, 2016-2021
Figure 4.26 Global Sales Revenues ($bn) for Influvac, Flumist and Inflexal, 2009-2021
Figure 4.27 Global Manufacturing Capacities (Doses) for Key Players, 2009
Figure 4.28 Projected Global Manufacturing Capacities (Doses) for Key Players, 2012
Figure 5.1 Influenza Vaccine Sales Revenues ($bn) for Mature Markets (US, Japan and EU5), 2009-2021
Figure 5.2 Average Vaccine Prices for the Mature Markets, 2009-2021
Figure 5.3 WHO Revenues for Global Seasonal Influenza Vaccine Manufacturing Capacity, 2009
Figure 5.4 Influenza Vaccine Sales Revenues ($bn) for the EU5 Markets, 2009-2021
Figure 5.5 Influenza Vaccine Sales Revenues ($bn) for Global, Mature and Emerging & Other Markets, 2009-2021
Figure 5.6 Influenza Vaccine Sales Revenues ($m) in the US, 2009-2021
Figure 5.7 Influenza Vaccine Market Shares (%) in the US, 2007-2008
Figure 5.8 Influenza Vaccine Market Shares (%) in the US, 2008-2009
Figure 5.9 Influenza Vaccine Production and Distribution for the US Market, 2000-2008
Figure 5.10 Average US Influenza Vaccines CDC Prices ($), 2002-2009
Figure 5.11 Influenza Vaccine Sales Revenues ($bn) in Japan, 2009-2021
Figure 5.12 Movement of Average Influenza Vaccine Price ($) per Unit in Japan, 2010-2021
Figure 6.1 Influenza Vaccine Sales Revenues ($bn) for Global, Mature and Emerging & Other Markets, 2010-2021
Figure 6.2 Influenza Vaccine Sales Revenues ($bn) in China, 2009-2021
Figure 6.3 Influenza Vaccine Sales Revenues ($bn) in India, 2009-2021
Figure 6.4 Summary of Influenza Vaccine Sales Revenues ($bn) in Emerging & Other Markets, 2009-2021
Figure 9.1 Crude Death Rate (CDR) in England, 1500-2000
Companies Listed
Abbott Laboratories
Acambis
ADImmune Corporation
Advisory Committee on Immunisation Practices (ACIP)
Alphavax
AmVac
Applied Microbiology/Vienna
Archimedes Development
Archimedes Pharma
Asian Development Bank
Asofarma
Astellas Pharma
AstraZeneca
Avir Green Hills Biotechnology
Bacilligen
Batelle Biomedical Research Center
Baxter
Baxter-Immuno AG
Bayer
Bayer Schering
Baylor College of Medicine
Becton Dickinson
Beijing Institute of Biological Products (BIBP)
Berna-Crucell
Bharat Biotech International Limited (BBIL)
BigDNA
Biken
Bill and Melinda Gates Foundation
Bio Farma
BioDiem
Biogenesis-Bago
Biological E
BiondVax Pharmaceuticals
Birmex Laboratories
Boryung
Burnet Institute
Butantan Institute
Cambridge Biostability (CBL)
Cantacuzino Institute
Carrington
CEL-SCI
Centre for Disease Control (CDC)
Changchun Changsheng Life Sciences Ltd
Changchun Institute of Biological Products (CCIBP)
Changzhou Yanshen Biotechnology Co.
Chemo Sero Therapeutic Research Institute
China National Biotec Group
Chiron
Cilian
Committee for Medicinal Products for Human Use (CHMP)
Connaught Laboratories
Corixa
Crucell
CSL Biotherapies
CytoGenix
Daichi Sankyo
DelSite
Denka Seiken
Department of Health (DoH, UK)
Department of Health and Human Services (HHS, US)
Dong Shin Pharmaceuticals
Dynavax
DynPort Vaccine Company
Elea
Emergent Biosolutions
European Centre for Disease Prevention and Control (ECDC)
European Committee for Medicinal Products for Human Use
European Medicines Agency (EMEA/EMA)
European Union (EU)
Evans Medical
Fiocruz
Food and Drug Administration (US FDA)
Fraunhofer Society
Gamma Vaccines
GAVI Alliance
Generex
GenVec
GlaxoSmithKline
Global Influenza Surveillance Network
GlobeImmune
Government Pharmaceutical Organization (GPO), Thailand
GPO Thailand
Green Cross Corporation
Green Hills Biotech
Health Industry Distributors Association (HIDA)
HemisphereRx
iBio
ID Biomedical
Immune Targeting Systems
Immunopreparat Research Productive Association
Immunovaccine
Indian Council of Medical Research (ICMR)
Influenza Vaccine Supply International Task Force
Inovio Pharmaceuticals
Institute of Experimental Medicine
Institute of Vaccines and Medical Biologicals (IVAC), Vietnam
Institute of Virology, Vaccines and Sera Torlak
Instituto Fundaco Butantan
Intercell
International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
InViragen
Iomai
Ivac
Jiangsu Yanshen
Johns Hopkins University, US
Juvaris
Kaketsuken
Kitasato Institute
Korea Green Cross
Korea Vaccine Co.
Lanzhou Institute of Biological Products (LIBP)
Liaoning Tiancheng Bio-pharmacy Institute Co.
LigoCyte Pharmaceuticals
Lipoxen
Liquidia
Lonza Group
Medeva
Medicago
MedImmune
Medirace
Mellow Hope
Merck & Co.
Microbix
Microgen
Mucosis
NanoBio
Nanotherapeutics
National Institute of Allergy and Infectious Diseases
National Network of Immunisation Information
Neptunus Interlong Bio-Technique Co Ltd
Netherlands Vaccine Institute (NVI)
NexBio
Nobilon International
Novartis
Novartis Vaccines and Diagnostics
Novavax
Omninvest
Omnivesta
Panacea Biotec
Pasteur Merieux Serums & Vaccins
PepTcell
Petrovax
PowderJect
PowderMed
Products Immunologicals and Drugs, Irkustk
Protein Sciences Corporation
Ranbaxy
Razi Vaccine and Serum Research Institute
RIVS, St Petersburg, Russian Federation
Sachsisches Serumwerk (SSW)
Sanofi Pasteur
Sanofi-Aventis
Serum Institute of India (SII)
Shanghai Institute of Biological Products (SIBP)
Shenzhen-Sanofi Pasteur
Shionogi
Simcere Pharmaceutical Group
Sinovac Biotech
Sinovac Kexing Biological Product Co.
Solvay Pharmaceuticals
State Food and Drug Administration (SFDA, China)
Takeda Pharmaceutical Company
The Biovac Institute
Theraclone
Torlak Institute
Toyama
UMN Pharma
UNICEF
University of Bergen, Norway
University of Ghent, Belgium
University of Oxford, UK
University of Pennsylvania, US
University of Queensland, Australia
University of Texas Medical, US
Vabiotech Vacsera
Variation Biotechnologies
Vaxart
Vaxine
VaxInnate Corp.
Vector Scientific Center, Russian Federation
Vical
World Health Organization (WHO)
Wyeth (now part of Pfizer)
Yeda
Zhejiang Tianyuan Bio-Pharmaceutical Corporation
